Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging

Ovarian cancer is amongst the most common types of cancer in women, with a relatively low overall cure rate of approximately 30%. This is therefore an important incentive to urge for further research in order to maximize the chances of survival for these patients. Intraperitoneal chemotherapy with Cisplatin is an effective treatement for ovarian cancer; however, many questions still remain concerning the ideal treatment protocol and tumor resistance towards the drug, which should be resolved for optimal application of this therapy. For the first time in-vivo grown tumors treated with both hyper- and normothermic intraperitoneal chemotherapy have been studied using nano-XRF spectroscopy to examine the platinum (Pt) distribution within the analyzed tissues. These measurements prove Pt resides predominantly outsides the cancer cells in the stroma of the tissue. These findings indicate the resistance mechanism of the cancer cells prevents Cisplatin from diffusing through their cell membranes. This is an important addition to the existing knowledge on the resistance mechanism providing insights which might help to overcome this effect. In our aim to find the optimal treatment protocol, no significant differences were found between the two examined procedures. A more extensive data set will be needed to draw definite conclusions.

[1]  Freddy C. Adams,et al.  A general Monte Carlo simulation of energy-dispersive X-ray fluorescence spectrometers—I: Unpolarized radiation, homogeneous samples , 1993 .

[2]  Dietrich Büsselberg,et al.  Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects , 2011, Cancers.

[3]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[4]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[5]  P. Moretto,et al.  Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. , 1996, Cellular and molecular biology.

[6]  F. Brenker,et al.  X-ray Fluorescence Nanotomography on Cometary Matter from Comet 81P/Wild2 Returned by Stardust , 2009 .

[7]  C. Coch,et al.  HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum‐based chemotherapy in patients with platinum‐sensitive recurrent epithelial ovarian cancer , 2014, International journal of cancer.

[8]  B. Lai,et al.  The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe. , 2003, Cancer research.

[9]  G. Bogani,et al.  Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey , 2014, Archives of Gynecology and Obstetrics.

[10]  Koen Janssens,et al.  A general Monte Carlo simulation of ED-XRF spectrometers. II: Polarized monochromatic radiation, homogeneous samples , 1995 .

[11]  M. Flessner,et al.  Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors , 2005, Clinical Cancer Research.

[12]  Koen Janssens,et al.  Analysis of X‐ray spectra by iterative least squares (AXIL): New developments , 1994 .

[13]  Philip S. Yu,et al.  Top 10 algorithms in data mining , 2007, Knowledge and Information Systems.

[14]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Martínez-Criado,et al.  Analysis of Platinum and Trace Metals in Treated Glioma Rat Cells by X-Ray Fluorescence Emission , 2014, Biological Trace Element Research.

[16]  P. Sugarbaker,et al.  Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients , 2012, Gastroenterology research and practice.

[17]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[18]  Tom Schoonjans,et al.  A general Monte Carlo simulation of energy dispersive X-ray fluorescence spectrometers — Part 5 Polarized radiation, stratified samples, cascade effects, M-lines , 2012 .

[19]  V. Rose,et al.  High-resolution fluorescence mapping of impurities in historical zinc oxide pigments: hard X-ray nanoprobe applications to the paints of Pablo Picasso , 2013 .

[20]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[21]  Judith Campisi,et al.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B , 2012, Nature Medicine.

[22]  Koen Janssens,et al.  Automated segmentation of μ‐XRF image sets , 1997 .

[23]  Tom Schoonjans,et al.  A general Monte Carlo simulation of energy-dispersive X-ray fluorescence spectrometers — Part 6. Quantification through iterative simulations , 2013 .

[24]  F. Brenker,et al.  In situ identification of a CAI candidate in 81P/Wild 2 cometary dust by confocal high resolution synchrotron X-ray fluorescence , 2009 .

[25]  Bert Masschaele,et al.  Dual detection X-ray fluorescence cryotomography and mapping on the model organism Daphnia magna , 2010, Powder Diffraction.

[26]  Sylvain Bohic,et al.  ID16B: a hard X-ray nanoprobe beamline at the ESRF for nano-analysis , 2016, Journal of synchrotron radiation.

[27]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[28]  B. Lai,et al.  Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity? , 2012, Dalton transactions.

[29]  J. Beijnen,et al.  Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  Nicole S. Bryce,et al.  Getting to the core of platinum drug bio-distributions: the penetration of anti-cancer platinum complexes into spheroid tumour models. , 2012, Metallomics : integrated biometal science.

[31]  F. Brenker,et al.  Nanoscopic X-ray fluorescence imaging of meteoritic particles and diamond inclusions. , 2014, Analytical chemistry.

[32]  G. Lajoie,et al.  Matrigel: A complex protein mixture required for optimal growth of cell culture , 2010, Proteomics.

[33]  Koen Janssens,et al.  Comparison of several background compensation methods useful for evaluation of energy-dispersive X-ray fluorescence spectra , 1995 .